Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

autologous natural killer cell-like CTLs

A preparation of cytotoxic T lymphocytes (CTLs) that express natural killer (NK)-like features (nCTLs), with potential immunomodulating and antineoplastic activities. The nCTLs are derived from autologous lymphocytes that have been in vitro exposed to autologous alpha-type-1 polarized dendritic cells that are pulsed with specific autologous tumor-associated antigens (TAAs); the nCTLs are subsequently expanded in the presence of the cytokine human interleukin-2 (IL-2). The generated nCTLs are potent CTLs that produce high amounts of granzyme B and perforin, and interferon-gamma (IFNg) with high killer activity and tumor-homing potential. Upon infusion of the autologous nCTLs, these cells specifically recognize the TAAs on the tumor cells, then bind to and directly lyse tumor cells.
Synonym:autologous aDC1-induced CTLs
autologous CTLs sensitized ex-vivo with autologous TAA-loaded alphaDC1
autologous natural killer-like cytotoxic lymphocytes
autologous nCTLs
autologous NK-like CTLs
in vitro DC-sensitized CTLs
in-vitro DC-sensitized autologous CTLs
therapeutic iNKT cells
therapeutic nCTLs
tumor neo-antigen-specific nCTLs
Search NCI's Drug Dictionary